Evidence map›Paper›PMID 38587552›Full record

ArticleCancer research2024

Transfer Learning Reveals Cancer-Associated Fibroblasts Are Associated with Epithelial-Mesenchymal Transition and Inflammation in Cancer Cells in Pancreatic Ductal Adenocarcinoma.

Samantha Guinn, Benedict Kinny-Köster, Joseph A Tandurella, Jacob T Mitchell, Dimitrios N Sidiropoulos, Melanie Loth, Melissa R Lyman, Alexandra B Pucsek, Daniel J Zabransky, Jae W Lee and 24 more

Open access · bronzeAbstract read
In one paragraph

Article in Cancer research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
9.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 42 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors at 4 institutions in 2 countries.

Samantha Guinn *Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-4558-8915
Benedict Kinny-Köster *Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0009-0003-7040-9725
Joseph A Tandurella *Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-5806-6681
Jacob T MitchellDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-5370-9692
Dimitrios N SidiropoulosDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0001-5716-3917
Melanie LothDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0003-2717-8258
Melissa R LymanDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-0091-0413
Alexandra B PucsekDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0001-7718-3341
Daniel J ZabranskyDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-8184-3346
Jae W LeeConvergence Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-0735-5707
Emma KartaliaDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0009-0000-6891-0498
Mili RamaniDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0009-0003-6714-691X
Toni T SeppäläDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-4940-3498
Christopher CherryBloomberg Kimmel Immunology Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-5481-0055
Reecha SuriDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0009-0004-7750-7931
Haley ZlomkeDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-3544-6841
Jignasha PatelDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0009-0003-1360-7709
Jin HeDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0001-9149-2247
Christopher L WolfgangDepartment of Surgery, New York University Grossman School of Medicine, New York, New York.ORCID 0009-0000-5817-6146
Jun YuDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0003-3435-6550
Lei ZhengDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0003-4163-2541
David P RyanThe Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-9685-673X
David T TingThe Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-3261-2322
Alec KimmelmanDepartment of Radiation Oncology at New York University Grossman School of Medicine, NYU Langone Health, New York, New York.ORCID 0009-0002-9465-8411
Anuj GuptaDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0009-0006-6692-9084
Ludmila DanilovaDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0003-2813-3094
Jennifer H ElisseeffBloomberg Kimmel Immunology Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-5066-1996
Laura D WoodConvergence Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0003-3096-652X
Genevieve Stein-O'BrienDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0001-8681-9110
Luciane T KagoharaDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0003-1706-0950
Elizabeth M JaffeeDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0003-3841-6549
Richard A Burkhart *Convergence Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0003-1087-0870
Elana J Fertig *Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0003-3204-342X
Jacquelyn W Zimmerman *Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-7775-2943
Bloomberg (United States) · USJohns Hopkins University · USMassachusetts General Hospital · USNew York University · US

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI WILLIAM George NELSON · 1985 to 2026
$208.6M
Transforming Human Pancreatic Cancer Into An Immunologic DiseaseP01CA247886 · NCI · JOHNS HOPKINS UNIVERSITY · PI AZAD, NILOFER S. · 2021 to 2025
$12.7M
Personalized preclinical models in pancreas cancer: a tractable approach to precision medicineK08CA248710 · NCI · JOHNS HOPKINS UNIVERSITY · PI BURKHART, RICHARD ANDREW · 2020 to 2024
$1.3M
Single-cell and imaging data integration software to spatially resolve the tumor microenvironmentU01CA253403 · NCI · JOHNS HOPKINS UNIVERSITY · PI FERTIG, ELANA · 2020 to 2022
$1.2M
Comprehensive Analysis and Multi-Omics Data Integration for Cancer-Related StudiesR50CA243627 · NCI · JOHNS HOPKINS UNIVERSITY · PI Ludmila Danilova · 2019 to 2026
$975k
Investigation of Immunotherapy-induced Alterations to Cellular Communication Networks in Pancreatic Ductal AdenocarcinomaF31CA284525 · NCI · JOHNS HOPKINS UNIVERSITY · PI MITCHELL, JACOB THOMAS · 2024 to 2024
$42k
NCI NIH HHS F31 CA284525NCI NIH HHS K08 CA248710NCI NIH HHS P01 CA247886NCI NIH HHS P30 CA006973NCI NIH HHS R50 CA243627NCI NIH HHS U01 CA253403
6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy characterized by an immunosuppressive tumor microenvironment enriched with cancer-associated fibroblasts (CAF). This study used a convergence approach to identify tumor cell and CAF interactions through the integration of single-cell data from human tumors with human organoid coculture experiments. Analysis of a comprehensive atlas of PDAC single-cell RNA sequencing data indicated that CAF density is associated with increased inflammation and epithelial-mesenchymal transition (EMT) in epithelial cells. Transfer learning using transcriptional data from patient-derived organoid and CAF cocultures provided in silico validation of CAF induction of inflammatory and EMT epithelial cell states. Further experimental validation in cocultures demonstrated integrin beta 1 (ITGB1) and vascular endothelial factor A (VEGFA) interactions with neuropilin-1 mediating CAF-epithelial cell cross-talk. Together, this study introduces transfer learning from human single-cell data to organoid coculture analyses for experimental validation of discoveries of cell-cell cross-talk and identifies fibroblast-mediated regulation of EMT and inflammation. SIGNIFICANCE: Adaptation of transfer learning to relate human single-cell RNA sequencing data to organoid-CAF cocultures facilitates discovery of human pancreatic cancer intercellular interactions and uncovers cross-talk between CAFs and tumor cells through VEGFA and ITGB1.

Indexed as

Cancer-Associated FibroblastsCarcinoma, Pancreatic DuctalCoculture TechniquesEpithelial-Mesenchymal TransitionInflammationIntegrin beta1Pancreatic NeoplasmsSingle-Cell AnalysisTumor MicroenvironmentCell CommunicationCell Line, TumorGene Expression Regulation, NeoplasticHumansNeuropilin-1OrganoidsVascular Endothelial Growth Factor AIntegrin beta1Itgb1 protein, humanNeuropilin-1Vascular Endothelial Growth Factor AVEGFA protein, human

Identifiers

PMID38587552
PMCPMC11065624
OpenAlexW4394579589

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.